Baxter Intl Inc Stock Price, News & Analysis

Baxter (NYSE:BAX) commenced tender offers on Nov. 19, 2025 to purchase its 2.600% senior unsecured notes due 2026 and a portion of its 1.915% senior unsecured notes due 2027.

The company will fund the offers subject to conditions using proceeds from a concurrent offering of new senior unsecured notes, and intends to use remaining proceeds to repay other indebtedness, including a term loan that had a $645 million outstanding balance as of Sept. 30, 2025.

Key dates: Early Tender Date Dec. 3, 2025; Price Determination Date Dec. 4, 2025; Expiration Dec. 18, 2025; anticipated settlement Dec. 22, 2025.

Baxter (NYSE:BAX) announced a quarterly cash dividend of $0.01 per share, payable on Jan. 2, 2026 to holders of record as of Nov. 28, 2025. The company said the indicated annual dividend rate is $0.04 per share. Management confirmed the reduction in the quarterly dividend will begin in January 2026 and is expected to free up more than $300 million in annual cash flow to accelerate deleveraging.

Baxter Foundation (NYSE:BAX) announced a $2.6 million, three-year grant to continue its partnership with Northwestern University School of Education and Social Policy to support the Baxter Center for Science Education (BCSE) in Chicagoland.

The funding sustains educator professional development, classroom lab supplies and student STEM experiences. Since 2009 the Foundation has provided nearly $9 million to the BCSE, which has reached about 260,000 students and trained nearly 4,000 teachers across 400+ schools in Cook and Lake counties.

Baxter (NYSE:BAX) will host a third-quarter 2025 financial results conference call on Thursday, October 30, 2025 at 7:30 a.m. Central Time. Investors can pre-register at the provided registration link to receive call details and join the live webcast on Baxter’s website. The call will be recorded and is copyrighted; recording or rebroadcast without permission is prohibited.

Baxter International (NYSE:BAX) has become the first manufacturer to receive the Gold Level Resiliency Badge from the Healthcare Industry Resilience Collaborative (HIRC) for IV Solutions, Nutrition Solutions, and Premix Drugs categories. This recognition follows the company's earlier achievements of HIRC Transparency Badges in 2023 and 2024.

The award highlights Baxter's excellence in five key areas: resilient global logistics and supply chain visibility, stronger cybersecurity frameworks, enhanced risk management and demand forecasting, inventory oversight, and operational health improvements. The company's Control Tower system provides real-time visibility into its global distribution network, enabling rapid response to emerging issues.

This recognition validates Baxter's commitment to building a more reliable and transparent healthcare supply chain, particularly crucial in maintaining the availability of critical medical supplies.

Baxter International (NYSE:BAX) has launched the Welch Allyn Connex 360 Vital Signs Monitor, a next-generation patient monitoring device that has received FDA 510(k) clearance. The device captures vital signs for adult, pediatric, and neonate patients, including blood pressure, temperature, pulse rate, respiration rate, and blood oxygen levels.

The Connex 360 features advanced connectivity through Baxter's cloud-based DeviceBridge platform, enabling automatic data transfer to electronic medical records. Key features include enhanced security with end-to-end encryption, customizable Early Warning Score protocols, and streamlined software upgrades. The device allows care teams to obtain a full set of patient vitals in less than one minute, supporting earlier detection of patient deterioration.

Baxter (NYSE:BAX) reported second-quarter 2025 results with sales from continuing operations reaching $2.81 billion, up 4% on a reported basis and 1% operationally. The company posted U.S. GAAP diluted EPS of $0.24 and adjusted diluted EPS of $0.59 from continuing operations.

Key segment performance included Medical Products & Therapies ($1.32B, flat reported/+1% operational), Healthcare Systems & Technologies ($767M, +3% reported/+2% operational), and Pharmaceuticals ($612M, +2% reported/+1% operational). The company recently appointed Andrew Hider as CEO to drive innovation and growth.

For full-year 2025, Baxter projects sales growth of 6-7% reported and 3-4% operational, with adjusted earnings guidance of $2.42-$2.52 per diluted share.

Baxter International (NYSE:BAX), a global medtech leader, has scheduled its second-quarter 2025 financial results conference call for Thursday, July 31, 2025, at 7:30 a.m. Central Time.

Investors and interested parties can pre-register for the call through a dedicated registration link. The conference call will also be accessible via webcast through Baxter's website. The company notes that the call recording is copyrighted material and cannot be recorded or rebroadcast without Baxter's permission.